Athenex, Inc (ATNX)(Nasdaq) Buy Limit $11.30 >>> Target $12.10
Nasdaq:ATNX
Athenex, Inc
Last News:
Athenex partner in China on go to launch TAEST therapy studies; shares up 2%
Athenex (ATNX +2.1%) announces that commercialization partner Xiangxue Pharmaceutical Company's subsidiary Xiangxue Life Sciences has received regulatory sign-off in China to start registration studies of T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy (candidate TAEST16001) in patients with solid tumors that are HLA-A*02:01-positive and NY-ESO-1-positive.
In July 2018, the companies established a joint venture, Axis Therapeutics Limited, to develop the TAEST technology.
---
Buy Limit - $11.30
Take Profit - $12.10
Stop Loss - $10.89
------
Take Profit = +7.17%
Stop Loss = -3.54%
Athenex, Inc
Last News:
Athenex partner in China on go to launch TAEST therapy studies; shares up 2%
Athenex (ATNX +2.1%) announces that commercialization partner Xiangxue Pharmaceutical Company's subsidiary Xiangxue Life Sciences has received regulatory sign-off in China to start registration studies of T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy (candidate TAEST16001) in patients with solid tumors that are HLA-A*02:01-positive and NY-ESO-1-positive.
In July 2018, the companies established a joint venture, Axis Therapeutics Limited, to develop the TAEST technology.
---
Buy Limit - $11.30
Take Profit - $12.10
Stop Loss - $10.89
------
Take Profit = +7.17%
Stop Loss = -3.54%
Anulowano zlecenie:
Cancelled
